Chad Terhune

Dr. Ali Sherif normally gives about 50 doses of the measles vaccine to children each month at his clinic in Hobbs, New Mexico, near the Texas state line.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.

Dozens of scientists, researchers and other employees at the U.S. National Institutes of Health issued a rare public rebuke Monday criticizing the Trump administration for major spending cuts that “harm the health of Americans and people across the globe,” politicize research and “waste public resources.”

Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation hearing.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs.

A Trump administration deal to cut prices for popular weight-loss drugs like Wegovy and Zepbound will allow millions more Americans to give them a try, but the cost may still be too high to keep patients long term, U.S. obesity specialists said.

Their Hepatitis B decision will expose more children to the virus, they said.

Medical device makers have been rushing to add AI to their products. While proponents say the new technology will revolutionize medicine, regulators are receiving a rising number of claims of patient injuries.

About a dozen times each day, medical staff at Parkside Pediatrics in Spartanburg, South Carolina, head to the clinic’s parking lot, reaching inside cars and minivans to check children and their parents for fever, rash and other signs of measles.